This introductory talk provides a brief overview for non-expert participants on the basic features of biologics and biosimilars and explains why these need to be distinguished from traditional small-molecule drugs. This will also include a basic summary of the most relevant legal frameworks and regulatory pathways that apply to biosimilars and an account of why innovators, policy makers, patients and other stakeholders should pay close attention to the recent developments in this increasingly important area of law and technology.